There have been several notable developments recently related to
Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH). Labcorp has introduced
FDA-approved self-collection tests for HPV and STIs, and launched an unprecedented
immunoassay to expedite Alzheimer's disease diagnosis. Furthermore, the corporation announced strong
Q1 2025 financial results, contributing to the perception of it as a reliable growth stock. Labcorp has also acquired assets from
BioReference Health's oncology and clinical testing services businesses, and released a groundbreaking
Alzheimer's blood test yielding 95% accuracy. Redburn Atlantic initiated Labcorp with a
$276 price target. The organization also successfully priced senior notes with totals of $650,000,000, $500,000,000 and $850,000,000, respectively. Labcorp's
Q4 2024 earnings and revenues surpassed expectations, despite turbulent margins causing an initial decline in its shares. The biotech giant is also planning to expand its credit facility to
$700 million, and recently finalized its acquisition of select assets from Invitae. Labcorp's stock further made gains from its recent acquisition of select assets from BioReference Health's diagnostics business. Lastly, Labcorp successfully completed its spin-off of
Fortrea.
Laboratory Corporation of America Holdings LH News Analytics from Sun, 19 Apr 2020 07:00:00 GMT to Thu, 03 Apr 2025 13:45:00 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor 6
